69337-85-5

Basic information

• Product Name: 2-(6-Methoxy-2-naphthyl)-2-methylpropanoic acid
• Synonyms: 2-(6-Methoxy-2-naphthyl)-2-methylpropanoic acid;2-(6-Methoxynaphthalen-2-yl)-2-Methylpropanoic acid
• CAS NO: 69337-85-5
• Molecular Formula: C15H16O3
• Molecular Weight: 244.28574
• Mol File: 69337-85-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 412.2°C at 760 mmHg
• Flash Point: 154.5°C
• Appearance: /
• Density: 1.169g/cm³
• Vapor Pressure: 1.55E-07mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: 2-8°C
• PKA: 4.90±0.30(Predicted)
• CAS DataBase Reference: 2-(6-Methoxy-2-naphthyl)-2-methylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-Methoxy-2-naphthyl)-2-methylpropanoic acid(69337-85-5)
• EPA Substance Registry System: 2-(6-Methoxy-2-naphthyl)-2-methylpropanoic acid(69337-85-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 69337-85-5(Hazardous Substances Data)

Usage

General Description

2-(6-Methoxy-2-naphthyl)-2-methylpropanoic acid, also known as MNA or Naproxen, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used for pain relief, inflammation, and fever reduction. It works by inhibiting the synthesis of prostaglandins, which are molecules involved in the body's inflammatory response. MNA is a derivative of propionic acid and has a methyl group attached to the second carbon atom, as well as a 2-naphthyl group with a methoxy (CH3O-) substitution at the 6 position. It is available in various forms such as tablets, syrups, and injections, and is commonly prescribed for conditions such as arthritis, menstrual cramps, and acute injuries. However, it also carries the risk of side effects such as gastrointestinal bleeding, cardiovascular problems, and kidney damage, and should only be used under a doctor's supervision.

InChI:InChI=1/C15H16O3/c1-15(2,14(16)17)12-6-4-11-9-13(18-3)7-5-10(11)8-12/h4-9H,1-3H3,(H,16,17)

Upstream product

• 30012-51-2 methyl 2-(6-methoxy-2-naphthyl)propionate 
• 23981-80-8 naproxen 
• 69337-84-4 methyl -2--(6--methoxynaphthalen--2--yl)--2--methylpropanoate 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION

Methods for selectively inhibiting endocannabinoid oxygenation but not arachidonic acid oxygenation. In some embodiments, the methods include contacting a COX-2 polypeptide with an effective amount of a substrate-selective COX-2 inhibitor. Also provided are methods for elevating a local endogenous cannabinoid concentrations; methods of reducing depletion of an endogenous cannabinoid; methods for inducing analgesia; methods of providing anxiolytic therapy; methods for providing anti-depressant therapy; and compositions for performing the disclosed methods.

The geminal dimethyl analogue of Flurbiprofen as a novel Aβ42 inhibitor and potential Alzheimer's disease modifying agent

The subtle modification of a selection of Aβ42 inhibiting non-steroidal anti-inflammatory drugs (NSAIDs), through synthesis of the geminal dimethyl analogues, was anticipated to ablate their cyclooxygenase activity whilst maintaining Aβ42 inhibition. Methylflurbiprofen 6 exhibited similar in vitro Aβ42 inhibition to its parent NSAID Flurbiprofen and was further evaluated in the Tg2576 mouse model of Alzheimer's disease and an animal model of gastro-intestinal (GI) impairment, but proved unviable for further clinical development.